Alzheimer's Association awards $4.3 million to accelerate the launch of new drug treatment arms in landmark prevention trial
The Alzheimer's Association announces a new $4.3 million research grant for a new phase of the Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU) known as DIAN-TU Next Generation (NexGen). This award will accelerate the testing of new potential Alzheimer's therapies and a new diagnostic approach in people with genetically based, younger-onset Alzheimer's disease using an innovative trial design that is being applied to Alzheimer's for the first time.
The Alzheimer's Association is the world's leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer's disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer's. For more information, visit www.alz.org.